A phase I-II trial of 4'-deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia.
In a phase I-II study, 21 patients with relapsed or refractory acute leukemia were treated with 4'-deoxydoxorubicin (esorubicin), the 4'-deoxy derivative of doxorubicin. Four of 14 evaluable patients with acute nonlymphocytic leukemia (ANLL) in relapse or refractory to other anthracyclines achieved partial response (28.5%). Pharmacokinetics were similar to those of the parent compound, doxorubicin. Esorubicin has activity in ANLL and has pharmacologic properties comparable to those of other anthracyclines. Dose-limiting toxicity occurs in the form of mucositis, which may limit its use in combination with other antileukemic drugs.
Dutcher
J P
JP
Albert Einstein Cancer Center/Montefiore Medical Center, New York.
Riggs
C E
CE
Strauman
J J
JJ
Link
B
B
Wiernik
P H
PH
D000328:Adult; D000368:Aged; D001752:Blast Crisis / Q000188:drug therapy; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009092:Mucous Membrane / Q000187:drug effects; D012074:Remission Induction
D004317:Doxorubicin; C030851:esorubicin